Eosinophilic Asthma Market
Report ID: SQMIG35I2981
Report ID: SQMIG35I2981
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I2981 |
Region:
Global |
Published Date: June, 2026
Pages:
157
|Tables:
145
|Figures:
78
Global Eosinophilic Asthma Market size was valued at USD 1.15 Billion in 2024 and is poised to grow from USD 1.21 Billion in 2025 to USD 1.81 Billion by 2033, growing at a CAGR of 5.16% during the forecast period (2026-2033).
The global eosinophilic asthma market involves therapies for a severe asthma condition marked by high eosinophil counts in the airways. The significance of this is the unmet clinical need for patients who still have frequent exacerbations despite conventional inhaled corticosteroids, and this has led to pharmaceutical investment in biologics such as mepolizumab and benralizumab. The market was a niche market until 2015, but the approval of the first anti-IL-5 monoclonal antibody by the FDA in 2015 resulted in a rapid uptake in the United States and Europe. Since then, payers have created reimbursement frameworks to broaden access to patients and sales have increased at a rate of over 30 percent a year in the public and private sectors.
The rise in urban pollution and aging populations is increasing the burden of severe asthma, intensifying the need for eosinophilic asthma and driving up clinician interest in precision medicines. The demographic shift means more insurance coverage for biologics, and drug makers are pouring money into next-generation therapies such as dupilumab that target interleukin-4/13 pathways. Registry study evidence also shows reductions in hospitalizations and improved quality of life with these agents, leading health systems to embed them into care pathways. Market players are therefore exploring opportunities in economies with better diagnostic capabilities thereby expanding the market beyond its traditional strongholds of North America and Europe.
How is AI-driven precision medicine shaping the eosinophilic asthma market?
Artificial intelligence-enabled precision medicine is reshaping the eosinophilic asthma market by correlating detailed biomarker profiles with treatment regimens. Machine-learning algorithms look at blood eosinophil counts, genetic signatures and real-world outcomes to predict which biologic drug will be most effective at reducing exacerbations for each patient. This data-driven approach allows clinicians to move past trial-and-error prescribing, cutting down the time to optimal control and overall healthcare utilization. Pharmaceutical developers are using AI platforms for trial design to accelerate the identification of responsive sub-populations and optimize dosing. This has resulted in an explosion of targeted therapies on the market that provide higher efficacy, better safety margins and a more patient-centric experience.
In January 2026, AstraZeneca launched Exdensur (depemokimab) after AI-guided patient stratification confirmed the benefit of the drug in severe eosinophilic asthma. This example demonstrates how precision tools drive drug adoption and build market momentum.
Market snapshot - (2026-2033)
Global Market Size
USD 1.15 Billion
Largest Segment
Corticosteroids
Fastest Growth
Biologic Therapies
Growth Rate
5.16% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global eosinophilic asthma market is segmented by drug product class, route of administration, patient demographics, distribution procurement channel, care setting environment and region. Based on drug product class, the market is segmented into Biologic Therapies, Corticosteroids, Bronchodilators and Leukotriene Modifiers. Based on route of administration, the market is segmented into Subcutaneous Injection, Intravenous Infusion, Oral Ingestion and Inhalation. Based on patient demographics, the market is segmented into Pediatric Patients, Adult Patients and Geriatric Patients. Based on distribution procurement channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on care setting environment, the market is segmented into Hospitals and Specialty Clinics and Home Healthcare Settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
The biologic therapies segment holds the largest share due to its ability to directly target eosinophilic inflammation and provide disease-modifying benefits that cannot be achieved with conventional therapies. Their mechanism aligns with the pathophysiology and underpins clinician preference and reimbursement support. This alignment will allow for sustained use in specialist practices, further cementing their role as central to therapeutic approaches. Severe eosinophilic phenotypes Patients are special beneficiaries with improved adherence and longer treatment courses thereby reinforcing market leadership.
However, the segment of leukotriene modifiers has the strongest growth momentum, as emerging data show synergistic effects with biologics expanding their utility beyond mild disease. Wider prescription of innovative fixed dose combinations and better safety perceptions, especially in patients who are averse to injections, are creating new therapeutic niches and accelerating market expansion.
The subcutaneous injection segment is projected to be dominant in 2022 because it delivers biologic therapies directly into the systemic circulation, offering rapid onset and consistent bioavailability, which are essential for the treatment of eosinophilic inflammation. The ability to administer at low volume in a clinic or by patients themselves, provides the convenience of not requiring complex infusion infrastructure and is compatible with both provider workflow and patient lifestyle preferences. This approach is sufficiently practical to be used in specialty care settings and incorporated into current treatment algorithms.
At the same time, the inhalation segment is emerging as the key high growth area, with advances in the engineering of devices capable of delivering precise dosing of novel small molecule agents that can complement biologics. Patient-friendly inhalers reduce treatment fatigue and allow prolonged use in community-based care, thus driving broader penetration in the market and opening up new opportunities for combination therapy development.
Meanwhile, inhalation segment is emerging as the key high growth area because advances in device engineering are delivering precise dosing of novel small molecule agents that complement biologics. Patient friendly inhalers reduce treatment fatigue and expand usage to community based care, driving broader market penetration and fostering new opportunities for combination therapy development.
To get detailed segments analysis, Request a Free Sample Report
As of 2025, North America holds the largest share of the global eosinophilic asthma market. The healthcare ecosystem in North America is mature, well-coordinated, and conducive to rapid adoption of innovative treatment. It is home to some of the world’s top pharmaceutical innovators and research institutions driving early clinical development and regulatory approvals. Strong payer frameworks and inclusive coverage policies remove financial barriers and promote increased use of specialty therapies. Strong patient awareness and advocacy networks, and integrated care models that ensure timely diagnosis and management also drive the demand. Together, these factors create an environment that is conducive to market leadership and sustainable growth.
The U.S. eosinophilic asthma market is driven by a high number of specialists and high adoption rates of advanced biologic therapies. There are all sorts of things that payers do to pay for care that help patients get care and physician education programs that improve diagnostic accuracy. Teamwork in research accelerates development of therapies. Patient groups promote awareness and lobby for particular treatments. These factors combine to make a dynamic market environment with rapid innovation and high utilization.
The Eosinophilic Asthma market is supported by universal health care in Canada, which facilitates equitable access to emerging therapies across provinces. There are strong clinical guidelines to support early identification and treatment and provincial formularies support the inclusion of specialty products. Real-world evidence from academic research centres is consistently published, which helps to increase clinician confidence. Awareness about the disease is also created by patient programs and education outreach which helps to create a supportive environment for market expansion.
Europe is growing through harmonised regulatory frameworks that are opening the market for innovative therapies and cross-border collaboration. Respiratory diseases are a target of public health efforts, so there is more screening and early treatment. Improved patient access is driven by the strong commitment of public and private payers to fund advanced treatments. Academic centers and industry partnerships create a pipeline for clinical data and integrated care pathways make delivery of treatment more efficient. All this adds up to a higher adoption rate and makes Europe a fast growing market.
Germany dominates the Eosinophilic Asthma market due to its strong research infrastructure and early uptake of new therapies. Reimbursement systems are designed to facilitate the use of high-cost specialty medicines and national guidelines promote targeted treatment strategies. The two engines of progress are the constant stream of innovation from university hospitals and biotech companies and the awareness and demand generated by patient advocacy groups. This ecosystem generates a potent, future-oriented marketplace.
The United Kingdom is the fastest growing market for Eosinophilic Asthma, as the National Health Service is prioritizing novel biologics in its therapeutic arsenal. Clinical pathways are tailored to precision medicine and funding models are changing to support new treatments . Strong research links between academia and industry accelerate the accumulation of evidence, and patient groups call for higher standards of care. Policy support and clinical excitement are driving a boom in the market.
France Eosinophilic Asthma market is one of the lucrative growth terrains with progressive health policies favoring adoption of innovative therapies. National guidelines are expanding and recognizing the value of targeted therapies with reimbursement processes changing to improve access. “There is a vital clinical knowledge being produced in research institutions. Patient education programs are increasing disease literacy. In this friendly setting, a faster market development is being initiated.
sia Pacific’s position is becoming stronger with growth in specialist care networks and a growing focus on respiratory health in public health agendas. Governments are investing in healthcare infrastructure and driving adoption of advanced therapies with progressive reimbursement models. Robust clinical research activity in the region produces valuable real-world evidence that provides clinicians confidence. Through growing patient awareness campaigns and partnerships with multinational biotech companies, the region continues to rapidly penetrate the market and establish itself as an increasingly influential player on the global scene.
Japan Eosinophilic Asthma Market is growing due to wide insurance coverage that helps in providing access to high‑value treatments. National clinical guidelines are a driving force in the field of precision diagnostics, and a robust culture of collaboration between academic hospitals and pharmaceutical companies promotes therapeutic innovation. Awareness-raising networks for patients lead to earlier detection and treatment uptake. These factors collectively create a fertile ground for consistent market growth.
The market for eosinophilic asthma in South Korea is backed by fast-changing healthcare policies that favor advanced therapeutics. Well-organized network of pulmonology specialists makes it possible to diagnose on time. Patients may be able to access cheaper funding through government-backed schemes. Local clinicians get valuable experience with new therapies by participating in multinational clinical trials. Educational outreach and patient support programs also help raise awareness of the disease, thus supporting the dynamic and growing market landscape.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Awareness of Severe Asthma
Emerging Biologic Therapeutic Options
High Cost of Biologic Treatments
Limited Long-Term Safety Data
Request Free Customization of this report to help us to meet your business objectives.
Big pharma companies are expanding their biologic and oral pipelines and new biotech companies are speeding up development through big funding rounds and strategic partnerships. This increases the pressure to develop differentiated eosinophilic asthma therapies. The market is driven by the search for targeted biologics, new small molecule oral drugs and inter-company licensing agreements to meet the needs of patients with no current treatment options..
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. As per SkyQuest analysis, the global eosinophilic asthma market is set to grow at a 5.2 % CAGR through 2033 as increasing awareness of severe asthma fuels earlier diagnosis and expands the pool of patients eligible for advanced treatments, while emerging biologic therapeutic options provide clinicians with more effective, disease‑modifying choices that further drive uptake. The market is led by North America, where a mature healthcare system and strong payer support accelerate adoption, and biologic therapies dominate the product landscape by directly targeting eosinophilic inflammation. However, the high cost of biologic treatments remains a restraint, limiting access in cost‑conscious markets and tempering overall penetration. Together, heightened disease awareness and innovative biologics are the twin engines propelling market expansion.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 1.15 Billion |
| Market size value in 2033 | USD 1.81 Billion |
| Growth Rate | 5.16% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Eosinophilic Asthma Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Eosinophilic Asthma Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Eosinophilic Asthma Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Eosinophilic Asthma Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Eosinophilic Asthma Market size was valued at USD 1.15 Billion in 2024 and is poised to grow from USD 1.21 Billion in 2025 to USD 1.81 Billion by 2033, growing at a CAGR of 5.16% during the forecast period (2026-2033).
The competitive landscape is shaped by major pharmaceutical groups expanding biologic and oral pipelines while emerging biotech firms accelerate development through sizable financing and strategic collaborations; this intensifies pressure to deliver differentiated eosinophilic asthma therapies, with market momentum driven by the pursuit of targeted biologics, novel small‑molecule oral agents, and cross‑company licensing arrangements that aim to capture unmet patient needs. 'GlaxoSmithKline plc', 'AstraZeneca plc', 'Teva Pharmaceutical Industries Ltd.', 'Sanofi S.A.', 'Regeneron Pharmaceuticals Inc.', 'Novartis AG', 'Roche Holding AG', 'Merck & Co. Inc.', 'Amgen Inc.', 'Boehringer Ingelheim International GmbH', 'Pfizer Inc.', 'Chiesi Farmaceutici S.p.A.', 'Shionogi & Co. Ltd.', 'Kiniksa Pharmaceuticals Ltd.', 'Pieris Pharmaceuticals Inc.', 'AB Science', 'Gossamer Bio Inc.', 'Knopp Biosciences', 'Synairgen plc', '4D Pharma plc'
Growing public and clinician awareness of eosinophilic asthma severity encourages earlier diagnosis and more proactive treatment, which expands the patient pool eligible for advanced therapies. Educational campaigns and guideline updates reinforce the condition’s distinct phenotype, prompting healthcare providers to consider targeted interventions. As physicians become more confident in identifying eosinophilic inflammation, prescribing rates for specialized biologics increase, directly driving market expansion through heightened product utilization and broader therapeutic adoption across respiratory care settings. This trend also stimulates pharmaceutical investment in research, further enriching the pipeline and reinforcing growth momentum.
Personalized Biologic Therapies: The market is shifting toward highly personalized biologic regimens that target specific eosinophilic pathways, driven by advances in companion diagnostics and patient stratification. Physicians are increasingly selecting agents based on biomarker profiles, disease severity, and comorbidity patterns, which enhances therapeutic efficacy and reduces unnecessary exposure. This patient‑centric approach is fostering stronger clinician‑patient relationships, encouraging adherence, and prompting manufacturers to develop niche formulations that align with individualized treatment plans across diverse healthcare settings globally, supporting sustainable market expansion and improved outcomes.
Why does North America Dominate the Global Eosinophilic Asthma Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
